{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:07Z","timestamp":1790712547337,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GGP17102"],"award-info":[{"award-number":["GGP17102"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02361928"],"award-info":[{"award-number":["RF-2016-02361928"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006601","name":"Ministero degli Affari Esteri e della Cooperazione Internazionale","doi-asserted-by":"publisher","award":["MAE00691612020-06-26"],"award-info":[{"award-number":["MAE00691612020-06-26"]}],"id":[{"id":"10.13039\/501100006601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jconrel.2020.12.051","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:34:24Z","timestamp":1610055264000},"page":"587-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease"],"prefix":"10.1016","volume":"330","author":[{"given":"Giulia","family":"Birolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ottonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Passoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Favagrossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Duskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Bombaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angela","family":"Vandelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Bagnati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Caccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Taroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Salmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.12.051_bb0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2020.07.007","article-title":"Delivering the power of nanomedicine to patients today","volume":"326","author":"Germain","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0015","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.nano.2009.02.005","article-title":"Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution","volume":"5","author":"Vergoni","year":"2009","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/nnm.11.11","article-title":"Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier","volume":"6","author":"Tosi","year":"2011","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2005.07.013","article-title":"Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier","volume":"108","author":"Costantino","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.05.022","article-title":"Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123","volume":"122","author":"Tosi","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00702-010-0497-1","article-title":"NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences","volume":"118","author":"Tosi","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2014.01.004","article-title":"Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport","volume":"177","author":"Tosi","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jconrel.2013.11.023","article-title":"Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution","volume":"174","author":"Vilella","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0065","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.294.5545.1354","article-title":"CNS synaptogenesis promoted by glia-derived cholesterol","volume":"294","author":"Mauch","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0070","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.1620506114","article-title":"Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism","volume":"114","author":"Ferris","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0075","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1523\/JNEUROSCI.3355-05.2005","article-title":"Dysfunction of the cholesterol biosynthetic pathway in Huntington\u2019s disease","volume":"25","author":"Valenza","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nbd.2007.07.004","article-title":"Progressive dysfunction of the cholesterol biosynthesis pathway in the R6\/2 mouse model of Huntington\u2019s disease","volume":"28","author":"Valenza","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0085","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/hmg\/ddm170","article-title":"Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation","volume":"16","author":"Valenza","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0090","doi-asserted-by":"crossref","first-page":"10844","DOI":"10.1523\/JNEUROSCI.0917-10.2010","article-title":"Cholesterol defect is marked across multiple rodent models of Huntington\u2019s disease and is manifest in astrocytes","volume":"30","author":"Valenza","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0095","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tins.2011.06.005","article-title":"Emerging roles for cholesterol in Huntington\u2019s disease","volume":"34","author":"Valenza","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2016.11.013","article-title":"Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington\u2019s disease: a cross-validation study in Q175 knock-in mice","volume":"98","author":"Shankaran","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0105","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/brain\/awn212","article-title":"Plasma 24Shydroxycholesterol and caudate MRI in pre-manifest and early Huntington\u2019s disease","volume":"131","author":"Leoni","year":"2008","journal-title":"Brain."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2013.03.013","article-title":"Plasma 24Shydroxycholesterol correlation with markers of Huntington disease progression","volume":"55","author":"Leoni","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0115","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrneurol.2011.132","article-title":"Cholesterol metabolism in Huntington disease","volume":"7","author":"Karasinska","year":"2011","journal-title":"Rev. Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0120","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.15252\/emmm.201505413","article-title":"Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington\u2019s disease mice","volume":"7","author":"Valenza","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0125","first-page":"1","article-title":"Striatal infusion of cholesterol promotes dose-dependent behavioral benefits and exerts disease-modifying effects in Huntington\u2019s disease mice","author":"Birolini","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/acschemneuro.9b00581","article-title":"Efficacy of cholesterol nose-to-brain delivery for brain targeting in Huntington\u2019s disease","volume":"11","author":"Passoni","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0135","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.03.061","article-title":"Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain","volume":"543","author":"Belletti","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20082014","article-title":"Targeting brain disease in MPSII: preclinical evaluation of IDS-loaded PLGA nanoparticles","volume":"20","author":"Rigon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0145","doi-asserted-by":"crossref","first-page":"102226","DOI":"10.1016\/j.nano.2020.102226","article-title":"Novel peptide-conjugated nanomedicines for brain targeting: in vivo evidence","volume":"28","author":"Duskey","year":"2020","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0150","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2020.12.051_bb0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013006475","article-title":"Poly (lactic-co-glycolic acid) controlled release systems: experimental and modeling insights","volume":"30","author":"Hines","year":"2013","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0160","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3389\/fphar.2018.01260","article-title":"PLGA-based nanoparticles in Cancer treatment","volume":"9","author":"Rezvantalab","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0165","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0170","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1039\/C4PY00039K","article-title":"Pluronic\u00ae block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances","volume":"5","author":"Pitto-Barry","year":"2014","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0175","first-page":"69","article-title":"Clinical trials for Huntington disease","author":"Rocha","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jconrel.2020.12.051_bb0180","first-page":"143","article-title":"Cytokines in Parkinson\u2019s disease","author":"Nagatsu","year":"2000","journal-title":"J. Neural Transm. Suppl."}],"updated-by":[{"DOI":"10.1016\/j.jconrel.2025.114346","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000}}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920307756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920307756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T07:59:32Z","timestamp":1763711972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920307756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":36,"alternative-id":["S0168365920307756"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.051","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.24.395525","asserted-by":"object"}]},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}